Jump to content

REL

From Wikipedia, the free encyclopedia
(Redirected from C-Rel)
REL
Identifiers
AliasesREL, C-Rel, REL proto-oncogene, NF-kB subunit, HIVEN86A, IMD92
External IDsOMIM: 164910; MGI: 97897; HomoloGene: 2182; GeneCards: REL; OMA:REL - orthologs
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_001291746
NM_002908

NM_009044

RefSeq (protein)

NP_001278675
NP_002899

NP_033070

Location (UCSC)Chr 2: 60.88 – 60.93 MbChr 11: 23.69 – 23.72 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

The proto-oncogene c-Rel is a protein that in humans is encoded by the REL gene.[5] The c-Rel protein is a member of the NF-κB family of transcription factors and contains a Rel homology domain (RHD) at its N-terminus and two C-terminal transactivation domains. c-Rel is a myeloid checkpoint protein that can be targeted for treating cancer.[6] c-Rel has an important role in B-cell survival and proliferation. The REL gene is amplified or mutated in several human B-cell lymphomas, including diffuse large B-cell lymphoma and Hodgkin's lymphoma.[7]

References

[edit]
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000162924Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000020275Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Ruben SM, Klement JF, Coleman TA, Maher M, Chen CH, Rosen CA (Jun 1992). "I-Rel: a novel rel-related protein that inhibits NF-kappa B transcriptional activity". Genes Dev. 6 (5): 745–60. doi:10.1101/gad.6.5.745. PMID 1577270.
  6. ^ Li T, Li X, Chen YH (May 2020). "c-Rel is a myeloid checkpoint for cancer immunotherapy". Nature Cancer. 1 (5): 507–517. doi:10.1038/s43018-020-0061-3. PMC 7808269. PMID 33458695.
  7. ^ Gilmore TD, Kalaitzidis D, Liang MC, Starczynowski DT (March 2004). "The c-Rel transcription factor and B-cell proliferation: a deal with the devil". Oncogene. 23 (13): 2275–86. doi:10.1038/sj.onc.1207410. PMID 14755244.

Further reading

[edit]
[edit]